Fluvastatin
| Clinical data | |
|---|---|
| Trade names | Lescol, others | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a694010 | 
| Pregnancy category | 
 | 
| Routes of administration | By mouth (capsules, tablets) | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 24–30% | 
| Protein binding | >98% | 
| Metabolism | Hepatic: CYP2C9 (75%), CYP3A4 (20%), CYP2C8 (5%) | 
| Elimination half-life | 1–3 hours (capsule), 9 hours (XR formulations) | 
| Excretion | Faeces (95%), urine (5%) | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.224.327 | 
| Chemical and physical data | |
| Formula | C24H26FNO4 | 
| Molar mass | 411.473 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Fluvastatin is a member of the statin drug class, used to treat hypercholesterolemia and to prevent cardiovascular disease.
It was patented in 1982 and approved for medical use in 1994. It is on the World Health Organization's List of Essential Medicines.